fda glp-1 compounding warning september 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Narrows Compounding Rules for

It's about building good lab habits that respect the science and the investment you've made in your research materials

More population-based data are urgently needed to determine whether selective blocking of ferroptosis can reverse testicular dysfunction

The muted experience of GLP-1 appetite suppression is a good thing taken too far

It is recommended to conduct more traditional observational and experimental studies in the future to explain the relationship between the two, aiming to more comprehensively reveal the relationship between micronutrients and GD, and provide stronger scientific evidence for the prevention and treatment of related diseases